Healthcare Industry News: AMPLATZER
News Release - June 11, 2007
AGA Medical Appoints Ronald E. Lund Chief Legal Officer
MINNEAPOLIS, June 11 (HSMN NewsFeed) -- AGA Medical Corporation ("AGA") today announced that it has appointed Ronald E. Lund as Chief Legal Officer, reporting directly to AGA Co-Founder, CEO and President, Franck Gougeon. Ron will advise AGA's senior management and board of directors on domestic and international legal strategies, compliance and intellectual property issues."Ron's experience in the health care industry, and at a medical technology company in particular, will be a tremendous asset for AGA Medical," said Franck Gougeon, President and CEO of AGA. "His counsel will help AGA continue to develop and produce innovative medical devices that can improve the well-being of millions. AGA continues to attract experts in their fields, and we welcome him to our team."
Before joining AGA, Ron was Of Counsel at the Minneapolis law firm Fredrikson & Byron, a position he will leave in his new advisory role with AGA. Ron is very active in the Minneapolis community. For the past 12 years, he has been a director of the Minnesota Orchestra, and for two years, ending in December, 2005, he served as Chairman of the Board of the Orchestral Association. He has a law degree from the University of Tennessee and a B.S. degree in Chemical Engineering from Iowa State University.
"I am very excited to be joining the AGA Medical team. This is a great company, with talented employees at every level, and sophisticated, life-saving products. I look forward to helping contribute to AGA's bright future," said Ron Lund.
ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis), is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the company has developed and commercialized a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart," such as atrial septal and patent foramen ovale defects. The company is expanding into new areas, including the minimally invasive repair of vascular abnormalities. Over 700 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices, such as improved patient outcomes, reduced length of stay and accelerated recovery times for the patient. AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 200,000 devices shipped to date. For more information visit www.AMPLATZER.com.
Source: AGA Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
